BioMedNewsBreaks

ThursdayMar 21, 2024 3:35 pm

BioMedNewsBreaks — Astiva Health Is Reshaping Healthcare Delivery

Astiva Health CEO Dr. Tri Nguyen was the featured guest in a recent Bell2Bell Podcast episode. “During the podcast, Nguyen provided an in-depth look at how Astiva Health is reshaping healthcare delivery, including an overview of the company’s commitment to patient involvement in healthcare and highlights of the company’s innovative strategies in offering comprehensive care… ‘So Astiva, other than providing full medical-care prescription drugs, we also focus on providing very rich supplemental benefits to our enrollees and getting them involved, participating and aiming for an active, healthy and meaningful life,’” reads a recent article, which contains quotes from the discussion.…

Continue Reading

ThursdayMar 21, 2024 12:34 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the report, key achievements during the period included enrolling the first patients for a pivotal trial studying AIMIGo(TM) System for synthesizing a 12-lead ECG as well as clinical and regulatory progress made for the AIMIGo 3D VECG system. In addition, the company noted it had received two new patents during the period, covering HeartBeam’s proprietary technologies. “We have continued to make…

Continue Reading

WednesdayMar 20, 2024 1:50 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the unmet medical needs of families with ASD – bringing hope to millions,” a recent article reads. “PaxMedica is using existing research on a drug called suramin, initially created to treat a disease called Human African…

Continue Reading

WednesdayMar 20, 2024 12:57 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares of common stock; the stocks and warrants are offered at a combined price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant. Genprex will be receive approximately $6.5 million in gross proceeds from the offering, before standard fees and…

Continue Reading

WednesdayMar 20, 2024 12:41 pm

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Developing Innovative Technologies to Address Critical Healthcare Challenges

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoPure(TM) to optimize chemotherapy delivery and reduce treatment toxicity. The company further disclosed that clinical site locations for first-in-human studies for Sigyn Therapy(TM) have been identified. Sigyn Therapy(TM) is a novel blood purification technology to treat pathogen-associated conditions that are beyond the reach of drugs,” a recent article reads. “Sigyn Therapeutics is developing innovative medical technologies to address critical healthcare challenges. The company’s technologies show promise in…

Continue Reading

WednesdayMar 20, 2024 12:29 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special stockholder meeting. According to the announcement, the reverse split will become effective at 11:59 p.m. ET on March 26, 2024. Following that, the company’s Class A common stock will begin trading on the NASDAQ Capital Market on a split-adjusted basis. “The reverse split is intended to increase the per share trading price of the company’s common stock to enable the…

Continue Reading

TuesdayMar 19, 2024 12:36 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Welcomes Seasoned Tech, Product-Development Veteran as New CTO

HealthLynked (OTCQB: HLYK), a leader in healthcare technology innovation, announced that Chris Hall will the company’s new chief technology officer (CTO). Hall has gained invaluable expertise in technology and product development throughout his career; specifically, he has been involved in the launch of more than 100 products, has been responsible for more than a dozen patents and has managed global diverse teams. He comes to HealthLynked from Battelle, where he served as a senior product portfolio manager, and from HF Scientific, where he served as manager of new product development. Prior to that, he spent almost 20 years with Siemens…

Continue Reading

TuesdayMar 19, 2024 12:29 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $4.09 per…

Continue Reading

TuesdayMar 19, 2024 12:07 pm

BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined the program to highlight information about the company’s work in the field of nanotechnology. “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the…

Continue Reading

FridayMar 15, 2024 2:05 pm

BioMedNewsBreaks — Astiva Health Addressing Challenges of Traditional Caregiving Structures

Astiva Health is a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities. The company is leading the charge in creating essential healthcare solutions tailored for the expanding aging Asian American community, which is undergoing a considerable demographic shift, with a growing segment of the population requiring more support. “The company is proactively meeting the unique needs of this group by providing healthcare services that are culturally sensitive and honor the diverse traditions and values across Asian cultures… Astiva Health’s commitment to culturally sensitive care acknowledges the importance of traditional values such as filial piety…

Continue Reading